文献速递其他结缔组织病

肿瘤TIF1基因突变与杂合性缺失与癌症相关肌病相关

Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

该研究对7例抗TIF1γ阳性癌症相关肌病(CAM)患者及对照的配对血液和肿瘤DNA进行全外显子测序,检测TIF1基因的体细胞突变和杂合性缺失(LOH),并用免疫组化H评分分析TIF1γ在皮肤、肌肉和肿瘤中的表达。结果显示抗TIF1γ阳性CAM患者肿瘤中TIF1基因突变和LOH增多(86% vs 17%;P=0.03),肿瘤和肌肉中TIF1γ染色更强,提示这些遗传改变可能与副肿瘤性肌病发生有关。

要点

  • 抗TIF1γ阳性CAM患者肿瘤中TIF1基因突变和LOH发生率为86%,高于TIF1γ阴性肌病患者的17%(P=0.03)。
  • 抗TIF1γ阳性患者肿瘤TIF1γ染色H评分255,高于非肌病对照肿瘤的196(P=0.01)。
  • 抗TIF1γ阳性患者肌肉TIF1γ染色H评分22,略高于抗TIF1γ阴性肌病患者的5(P=0.03)。

核心结论

  • 副肿瘤性抗TIF1γ阳性患者的肿瘤中TIF1基因突变和LOH等遗传改变增多,结合肿瘤、肌肉和皮肤中TIF1γ高表达,可能是理解副肿瘤性肌病发生的关键。

研究设计与样本

  • 对7例抗TIF1γ阳性CAM患者及对照的配对血液和肿瘤DNA进行全外显子测序,检测TIF1基因的体细胞突变和LOH。
  • 采用免疫组化H评分研究TIF1γ在CAM累及的不同组织(皮肤、肌肉和肿瘤)中的表达。

主要发现

  • 7例抗TIF1γ阳性CAM患者中检测到1个体细胞突变和5例一个或多个TIF1基因的LOH,而TIF1γ阴性肌病患者肿瘤中仅1例LOH(86% vs 17%;P=0.03)。
  • 与非肌病患者的类型匹配对照肿瘤相比,抗TIF1γ阳性患者肿瘤中TIF1γ染色更强(H评分255 vs 196;P=0.01)。
  • 抗TIF1γ阳性患者肌肉中TIF1γ染色略强于抗TIF1γ阴性肌病(H评分22 vs 5;P=0.03)。
  • 肌病和对照患者皮肤中均检测到强烈的TIF1γ染色。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To analyse the influence of genetic alterations and differential expression of transcription intermediary factor 1 (TIF1) genes in the pathophysiology of cancer-associated myositis (CAM). METHODS: Paired blood and tumour DNA samples from patients with anti-TIF1γ-positive CAM and from controls were analysed by whole-exome sequencing for the presence of somatic mutations and loss of heterozygosity (LOH) in their TIF1 genes. The genesis and maintenance of the autoimmune process were investigated immunohistochemically by studying TIF1γ expression in the different tissues involved in CAM (skin, muscle and tumour) based on the immunohistochemical H-score. RESULTS: From seven patients with anti-TIF1γ-positive CAM, we detected one somatic mutation and five cases of LOH in one or more of the four TIF1 genes compared with just one case of LOH in tumours from TIF1γ-negative myositis patients (86% vs 17%; P = 0.03). Compared with type-matched control tumours from non-myositis patients, TIF1γ staining was more intense in tumours from anti-TIF1γ-positive patients (H-score 255 vs 196; P = 0.01). Also, TIF1γ staining in muscle was slightly more intense in anti-TIF1γ-positive than in anti-TIF1γ-negative myositis (H-score 22 vs 5; P = 0.03). In contrast, intense TIF1γ staining was detected in the skin of both myositis and control patients. CONCLUSION: Tumours from paraneoplastic anti-TIF1γ-positive patients showed an increased number of genetic alterations, such as mutations and LOH, in TIF1 genes. These genetic alterations, in the context of a high expression of TIF1γ in the tumour, muscle and skin of these patients may be key to understanding the genesis of paraneoplastic myositis.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Pinal-Fernandez I, Ferrer-Fabregas B, Trallero-Araguas E, et al. Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis. Rheumatology (Oxford). 2018. PMID: 29149307. doi:10.1093/rheumatology/kex413

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。